Non-Alcoholic Fatty Liver Disease (NAFLD): The Most Comprehensive Guide to Understanding and Reversing Fatty Liver Naturally

Your liver is one of the hardest-working organs in your body — performing over 500 functions daily. When fat begins to accumulate in liver cells without alcohol as the cause, we call it Non-Alcoholic Fatty Liver Disease (NAFLD). It's now the most common liver condition worldwide — and in many cases, it's entirely reversible with the right approach.

What Is NAFLD?

NAFLD is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. It is characterised by excess fat (lipid) accumulation in liver cells (hepatocytes), affecting more than 5% of liver weight.

NAFLD exists on a spectrum:

• Simple steatosis (fatty liver) — fat accumulation with minimal inflammation; often fully reversible
• Non-Alcoholic Steatohepatitis (NASH) — fat plus active inflammation and liver cell damage (ballooning); higher risk of progression
• Fibrosis (F1–F3) — progressive scarring of liver tissue as a result of ongoing inflammation
• Cirrhosis (F4) — advanced, diffuse scarring that severely impairs liver function
• Hepatocellular carcinoma (HCC) — liver cancer; a risk in advanced, untreated cirrhosis

How Common Is NAFLD?

NAFLD affects approximately 25–30% of the global adult population, making it the leading cause of chronic liver disease worldwide. In New Zealand and Australia, prevalence mirrors global trends, with rates rising in parallel with obesity, metabolic syndrome, and type 2 diabetes.

Concerningly, NAFLD is increasingly being diagnosed in children and adolescents, driven by rising rates of childhood obesity, sedentary behaviour, and high-sugar diets. Paediatric NAFLD is now estimated to affect 7–10% of children globally, rising to 34–38% in obese children.

The Pathophysiology of NAFLD: How It Actually Develops

Understanding how NAFLD develops helps explain why the multi-modal treatment approach is so effective.

The "Multiple Parallel Hits" Model

Early research proposed a "two-hit" model — first, fat accumulates in the liver (steatosis), then a second insult (oxidative stress, inflammation) triggers NASH. Current understanding has evolved to a "multiple parallel hits" model, recognising that several simultaneous processes drive NAFLD progression:

Hit 1 — Lipid accumulation: Excess dietary carbohydrates (particularly fructose) and saturated fats overwhelm the liver's capacity to process and export fat. De novo lipogenesis (new fat synthesis) is upregulated, and fatty acid oxidation is impaired.

Hit 2 — Oxidative stress: Excess fat in hepatocytes undergoes lipid peroxidation, generating reactive oxygen species (ROS) that damage cell membranes, DNA, and mitochondria.

Hit 3 — Mitochondrial dysfunction: Chronic fat overload impairs mitochondrial electron transport chain function, reducing ATP production and increasing ROS generation — a vicious cycle.

Hit 4 — Endoplasmic reticulum (ER) stress: The ER, responsible for protein folding and lipid metabolism, becomes overwhelmed, triggering inflammatory signalling cascades (unfolded protein response/UPR).

Hit 5 — Gut-liver axis dysregulation: Increased intestinal permeability ("leaky gut") allows bacterial endotoxins (lipopolysaccharide/LPS) to enter portal circulation and reach the liver, activating Kupffer cells (liver immune cells) and driving inflammation via TLR4 signalling.

Hit 6 — Adipose tissue inflammation: Dysfunctional visceral fat releases pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and free fatty acids directly into portal circulation, compounding hepatic inflammation.

Hit 7 — Epigenetic and genetic factors: Gene variants (PNPLA3 I148M, TM6SF2 E167K, MBOAT7) alter lipid metabolism and inflammatory responses, explaining why some individuals develop NASH while others remain at simple steatosis.

Fibrosis Staging: What the Numbers Mean

Liver fibrosis is staged F0–F4 based on biopsy or non-invasive testing:

• F0 — No fibrosis; liver architecture normal
• F1 — Mild fibrosis; perisinusoidal or periportal fibrosis
• F2 — Moderate fibrosis; perisinusoidal and portal/periportal fibrosis
• F3 — Severe fibrosis; bridging fibrosis connecting portal tracts
• F4 — Cirrhosis; diffuse nodular scarring; irreversible in most cases

Clinical significance: F0–F2 is generally reversible with lifestyle intervention. F3 may partially reverse. F4 (cirrhosis) is largely irreversible, though progression can be halted and some functional improvement is possible.

The NAFLD Activity Score (NAS) is used in biopsy grading and scores three features: steatosis (0–3), lobular inflammation (0–3), and hepatocyte ballooning (0–2). A NAS ≥5 is generally consistent with NASH.

How Common Is NAFLD?

NAFLD affects approximately 25–30% of the global adult population, making it the leading cause of chronic liver disease worldwide. In New Zealand and Australia, prevalence mirrors global trends, with rates rising alongside obesity and metabolic syndrome.

Root Causes & Risk Factors

NAFLD is fundamentally a metabolic disease. Key drivers include:

• Insulin resistance — the primary underlying mechanism in most cases
• Obesity — particularly central/visceral adiposity; BMI >30 carries 4–5x higher NAFLD risk
• Type 2 diabetes and pre-diabetes — up to 70% of T2D patients have NAFLD
• Metabolic syndrome — a cluster of high blood pressure, high triglycerides, low HDL, elevated blood sugar, and abdominal obesity
• Hypothyroidism — thyroid hormone regulates hepatic fat metabolism; even subclinical hypothyroidism increases NAFLD risk
• Polycystic ovarian syndrome (PCOS) — insulin resistance and androgen excess drive hepatic fat accumulation
• Sleep apnoea — intermittent hypoxia drives oxidative stress and liver inflammation; independent NAFLD risk factor
• Gut dysbiosis — altered gut microbiome increases intestinal permeability and liver exposure to bacterial endotoxins
• Genetic factors — PNPLA3, TM6SF2, MBOAT7 variants increase susceptibility
• Certain medications — corticosteroids, tamoxifen, methotrexate, amiodarone, valproate
• Rapid weight loss — paradoxically, very rapid weight loss can worsen NAFLD by mobilising large amounts of free fatty acids to the liver

NAFLD in Specific Populations

Women with PCOS

PCOS is one of the most underrecognised risk factors for NAFLD in women of reproductive age. Insulin resistance, hyperandrogenism, and dyslipidaemia create a perfect metabolic storm for hepatic fat accumulation. Studies show NAFLD prevalence of 30–70% in women with PCOS, often independent of BMI. Addressing insulin resistance is the cornerstone of management in this group.

Hypothyroid Patients

Thyroid hormone (T3) directly regulates hepatic lipid metabolism, mitochondrial function, and cholesterol clearance. Even subclinical hypothyroidism (elevated TSH with normal T4) is associated with significantly increased NAFLD risk and more severe fibrosis. Optimising thyroid function is an important and often overlooked component of NAFLD management.

Post-Menopausal Women

Oestrogen has hepatoprotective effects — it promotes fat oxidation and reduces hepatic lipid accumulation. After menopause, the loss of oestrogen accelerates visceral fat gain and worsens insulin resistance, significantly increasing NAFLD risk. Post-menopausal women have NAFLD rates approaching those of men.

Children and Adolescents

Paediatric NAFLD is driven primarily by obesity, high-fructose diets, and sedentary behaviour. Children with NAFLD are at significantly elevated risk of cardiovascular disease and type 2 diabetes in adulthood. Dietary intervention and exercise are the primary treatments; no medications are approved for paediatric NAFLD.

Lean NAFLD

Approximately 10–20% of NAFLD cases occur in individuals with a normal BMI — so-called "lean NAFLD." These individuals often have normal or near-normal metabolic markers but carry visceral fat disproportionate to their BMI, have gut dysbiosis, genetic susceptibility, or dietary patterns high in fructose. Lean NAFLD can be more aggressive than obesity-associated NAFLD.

The Insulin Resistance Connection

Insulin resistance is the central driver of NAFLD and deserves particular attention. When cells become resistant to insulin's signal, the pancreas compensates by producing more insulin (hyperinsulinaemia). This elevated insulin:

• Stimulates de novo lipogenesis (new fat production) in the liver via SREBP-1c activation
• Impairs fatty acid oxidation (fat burning) by suppressing PPARα
• Increases free fatty acid delivery to the liver from adipose tissue via hormone-sensitive lipase activation
• Promotes inflammation via activation of NF-κB and JNK inflammatory pathways
• Impairs VLDL export — reducing the liver's ability to export fat into circulation

This creates a vicious cycle — more fat in the liver worsens insulin resistance, which drives more fat accumulation.

Key markers to assess insulin resistance:

• Fasting insulin (optimal: <7 mIU/L; >12 mIU/L indicates significant resistance)
• HOMA-IR score (optimal: <1.5; >2.5 indicates insulin resistance)
• Fasting glucose and HbA1c
• Triglyceride:HDL ratio (optimal: <2; >3 strongly suggests insulin resistance)
• Uric acid (elevated levels correlate with fructose intake, insulin resistance, and NAFLD)
• Fasting triglycerides (optimal: <1.5 mmol/L)

Signs & Symptoms

NAFLD is often called a "silent" disease — most people have no symptoms in early stages. When symptoms do occur, they may include:

• Fatigue and low energy (often the first and most common symptom)
• Mild discomfort or heaviness in the upper right abdomen
• Elevated liver enzymes on blood tests (ALT, AST, GGT)
• Brain fog and poor concentration
• Poor digestion, bloating, and sluggish bowel function
• Difficulty losing weight despite dietary effort

In advanced stages (NASH, fibrosis, cirrhosis):

• Jaundice (yellowing of skin/eyes)
• Fluid retention in the abdomen (ascites)
• Easy bruising and bleeding
• Spider angiomas (small spider-like blood vessels on skin)
• Muscle wasting (sarcopenia)
• Confusion and cognitive impairment (hepatic encephalopathy)

---

Diagnosis

NAFLD is typically identified through:

• Liver function tests (LFTs) — elevated ALT and AST (though normal LFTs do not rule out NAFLD; up to 80% of NAFLD patients have normal ALT)
• GGT — often elevated; sensitive marker of liver stress and oxidative burden
• Ultrasound — most common imaging tool; detects fat accumulation but cannot assess fibrosis or inflammation
• FibroScan (transient elastography) — non-invasive assessment of liver stiffness/fibrosis; widely available in NZ
• MRI-PDFF (proton density fat fraction) — gold standard for quantifying liver fat non-invasively
• Liver biopsy — definitive diagnosis of NASH and fibrosis staging; invasive, reserved for complex or uncertain cases
• FIB-4 score — calculated from age, ALT, AST, and platelet count; estimates fibrosis risk (score <1.3 = low risk; >2.67 = high risk)
• NAFLD Fibrosis Score (NFS) — another non-invasive fibrosis calculator using age, BMI, glucose, ALT, AST, platelets, and albumin

The Diet Connection

Diet is one of the most powerful levers for reversing NAFLD. Clinical evidence supports the following:

Foods to Prioritise

• Extra virgin olive oil — rich in oleocanthal and oleic acid; reduces liver fat and inflammation; Mediterranean diet studies show significant NAFLD benefit
• Oily fish — salmon, sardines, mackerel; omega-3 fatty acids reduce hepatic triglycerides and inflammation
• Cruciferous vegetables — broccoli, Brussels sprouts, cauliflower; support liver detoxification via sulforaphane and indole-3-carbinol
• Leafy greens — spinach, kale, rocket; reduce fat deposition in the liver; high in folate supporting methylation
• Walnuts — high in omega-3 ALA and polyphenols; associated with improved liver enzymes in clinical studies
• Avocado — contains beta-sitosterol, glutathione precursors, and oleic acid; reduces liver fat in animal models
• Berries — blueberries, raspberries; anthocyanins reduce oxidative stress and liver inflammation
• Green tea — EGCG reduces liver fat and ALT levels in clinical trials; 3–5 cups daily or concentrated extract
• Coffee — 2–3 cups daily consistently associated with reduced liver fibrosis, lower NASH risk, and reduced HCC risk; independent of caffeine (likely via chlorogenic acids and diterpenes)
• Legumes — lentils, chickpeas, black beans; improve insulin sensitivity, reduce liver fat, and provide prebiotic fibre
• Eggs — rich in choline, essential for hepatic fat export; do not avoid eggs in NAFLD
• Garlic — allicin and S-allylcysteine reduce liver fat and inflammation in clinical trials

Foods to Avoid or Minimise

• Fructose and added sugars — fructose is metabolised almost exclusively in the liver and directly drives de novo lipogenesis; high-fructose corn syrup is particularly harmful; limit to <25g added sugar daily
• Sugar-sweetened beverages — soft drinks, fruit juices, energy drinks; even 100% fruit juice raises liver fat
• Refined carbohydrates — white bread, pasta, pastries, breakfast cereals; rapidly raise blood glucose and insulin
• Ultra-processed foods — high in seed oils, additives, emulsifiers, and refined ingredients; disrupt gut microbiome
• Saturated fat in excess — particularly from processed meats and fried foods
• Alcohol — even moderate intake (1–2 standard drinks/day) accelerates NAFLD progression; abstinence recommended in NASH
• Trans fats — partially hydrogenated oils found in some packaged foods; directly promote liver inflammation

Understanding Fructose: The Key Dietary Driver

Fructose deserves special attention. Unlike glucose, which is metabolised by all cells, fructose is almost exclusively metabolised in the liver. When consumed in excess:

1. It bypasses normal glycolytic regulation and is rapidly converted to fat (de novo lipogenesis)
2. It generates uric acid as a byproduct, which independently promotes insulin resistance and liver inflammation
3. It depletes hepatic ATP, impairing mitochondrial function
4. It activates ChREBP and SREBP-1c, master regulators of fat synthesis

Practical fructose guidance:

• Whole fruit is generally safe — fibre slows absorption and limits dose
• Fruit juice, dried fruit, and smoothies concentrate fructose without fibre — limit these
• Read labels: high-fructose corn syrup, fructose, agave, and "fruit concentrate" are all high-fructose ingredients
• Aim for <25g added sugar daily; ideally <15g for active NAFLD management

Choline: The Overlooked Nutrient

Choline is essential for the synthesis of phosphatidylcholine, a key component of VLDL particles that export fat from the liver. Choline deficiency directly causes fatty liver — it is one of the most reliable ways to induce NAFLD in animal models.

Best food sources of choline:

Adequate intake: 425mg/day (women), 550mg/day (men). Many people — particularly those on plant-based diets — fall well short of this.

Dietary Patterns with Clinical Evidence

• Mediterranean diet — most evidence-backed dietary pattern for NAFLD; reduces liver fat, inflammation, and fibrosis risk; associated with 40% lower NASH risk in observational studies
• Low-carbohydrate / ketogenic diet — rapidly reduces liver fat (often within 2 weeks) through reduced insulin and de novo lipogenesis; effective short-to-medium term intervention; monitor lipids
• Time-restricted eating (intermittent fasting) — improves insulin sensitivity and reduces liver fat; 16:8 protocol well-studied; reduces hepatic glucose production overnight

Sample 3-Day Meal Plan (Mediterranean/Low-Glycaemic)

Day 1

• Breakfast: 2 eggs scrambled with spinach and avocado, black coffee or green tea
• Lunch: Grilled salmon with rocket, cucumber, olives, and extra virgin olive oil dressing
• Dinner: Lentil and vegetable soup with a side of steamed broccoli
• Snacks: Walnuts, blueberries

Day 2

• Breakfast: Full-fat Greek yoghurt with mixed berries and a tablespoon of ground flaxseed
• Lunch: Chicken and chickpea salad with leafy greens, tomato, and tahini dressing
• Dinner: Baked mackerel with roasted Brussels sprouts and cauliflower
• Snacks: Celery with almond butter, green tea

Day 3

• Breakfast: Vegetable omelette (2 eggs, mushrooms, spinach, garlic) cooked in olive oil
• Lunch: Sardines on rye crackers with avocado and cucumber
• Dinner: Grass-fed beef stir-fry with bok choy, broccoli, and garlic over cauliflower rice
• Snacks: A small handful of mixed nuts, herbal tea

Lifestyle Interventions

Weight Loss

A 5–10% reduction in body weight is associated with significant improvements in liver fat and inflammation. A >10% reduction can reverse NASH and reduce fibrosis. A >7% weight loss is the threshold most consistently associated with histological improvement in NASH. Even modest weight loss has meaningful clinical impact — do not underestimate small, sustained changes.

Important caveat: Rapid weight loss (>1.5kg/week) can paradoxically worsen NAFLD by flooding the liver with free fatty acids from rapidly mobilised adipose tissue. Aim for 0.5–1kg/week.

Exercise

Both aerobic and resistance training independently reduce liver fat, even without weight loss — exercise has direct hepatic benefits beyond its effect on body weight.

Aerobic exercise:

• 150–300 minutes per week of moderate intensity (brisk walking, cycling, swimming)
• Even 30 minutes of brisk walking 5 days/week reduces liver fat measurably
• Higher intensity yields greater benefit — vigorous exercise (jogging, cycling at effort) is more effective per minute

Resistance training:

• 2–3 sessions per week; improves insulin sensitivity, reduces visceral fat, and builds metabolically active muscle
• Muscle mass is a major glucose sink — more muscle = better insulin sensitivity = less liver fat

HIIT (High-Intensity Interval Training):

• Shown to reduce liver fat more efficiently than moderate continuous exercise in several RCTs
• 20–30 minutes, 3x/week is sufficient
• Example protocol: 30 seconds hard effort, 90 seconds recovery, repeat 8–10 times

8-Week Progressive Exercise Plan for NAFLD:

Sleep

Poor sleep and sleep apnoea are independently associated with NAFLD progression. Intermittent hypoxia from sleep apnoea drives oxidative stress, inflammation, and insulin resistance — all of which worsen liver disease.

Sleep hygiene protocol for metabolic health:

• Aim for 7–9 hours per night consistently
• Maintain consistent sleep/wake times (even weekends)
• Avoid screens 60 minutes before bed (blue light suppresses melatonin)
• Keep bedroom cool (18–20°C) and dark
• Avoid eating within 2–3 hours of sleep — overnight fasting supports hepatic fat oxidation
• If snoring or daytime fatigue is present, investigate for sleep apnoea (home sleep study available in NZ)

Stress Management & the HPA Axis

Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol. Chronically elevated cortisol:

• Promotes visceral fat accumulation (cortisol receptors are dense in visceral adipose tissue)
• Drives insulin resistance via gluconeogenesis and glucose mobilisation
• Increases appetite for high-calorie, high-sugar foods
• Impairs sleep quality, compounding metabolic dysfunction

Evidence-based stress reduction strategies:

• Mindfulness-based stress reduction (MBSR) — 8-week programmes shown to reduce cortisol and improve metabolic markers
• Yoga — reduces cortisol, improves insulin sensitivity, and has been studied specifically in NAFLD with positive results
• Breathwork — diaphragmatic breathing activates the parasympathetic nervous system; 5–10 minutes daily reduces HPA activation
• Nature exposure — "forest bathing" (Shinrin-yoku) reduces cortisol and inflammatory markers in clinical studies
• Social connection — chronic loneliness elevates inflammatory cytokines; prioritise meaningful relationships

Reducing Environmental Toxin Exposure

Endocrine-disrupting chemicals (EDCs) impair liver detoxification and metabolic function. Key offenders include:

• BPA and BPS — found in plastic containers, tin can linings, and thermal receipts; disrupt insulin signalling
• Phthalates — found in plastics, personal care products, and food packaging; impair mitochondrial function
• Pesticides — organophosphates and glyphosate disrupt gut microbiome and liver detoxification
• PFAS ("forever chemicals") — found in non-stick cookware, food packaging, and water; accumulate in liver tissue

Practical reduction strategies:

• Choose glass, stainless steel, or ceramic food storage
• Filter drinking water (reverse osmosis or activated carbon)
• Choose organic produce for the "Dirty Dozen" (strawberries, spinach, apples, grapes, etc.)
• Switch to natural personal care and cleaning products
• Avoid heating food in plastic containers

Herbal Medicine for NAFLD

Milk Thistle (Silybum marianum)

The most extensively studied herb for liver conditions. Its active constituent silymarin (particularly silybin) has demonstrated:

• Hepatoprotective effects — protects liver cells from oxidative damage and lipid peroxidation
• Anti-inflammatory action — inhibits NF-κB, TNF-α, and pro-inflammatory cytokines
• Antifibrotic properties — inhibits hepatic stellate cell activation and collagen deposition
• Improved insulin sensitivity — silybin improves glucose uptake and reduces HOMA-IR
• Reduction in ALT, AST, and GGT in multiple clinical trials
• Emerging evidence for reduction in liver fat on imaging

Bioavailability note: Standard silymarin has poor oral bioavailability (~23–47%). Liposomal and phytosome formulations significantly enhance absorption — choose these where possible.

We stock several high-quality milk thistle options: Natroceutics Liposomal Milk Thistle 60caps, Natroceutics Milk Thistle 60 Capsules, Coyne Liposomal Bio-Milk Thistle Complex 30caps, and Lifestream Milk Thistle 60vcaps. For a comprehensive liver formula, consider Designs for Health Hepatatone Plus 120VC.

Clinical dose: 420–600mg silymarin daily in divided doses. Liposomal forms: follow product dosing.

Dandelion (Taraxacum officinale)

• Choleretic and cholagogue — stimulates bile production and flow, supporting fat digestion and liver detoxification
• Reduces hepatic lipid accumulation in animal and in vitro studies
• Anti-inflammatory via luteolin and chicoric acid
• Supports kidney elimination of metabolic waste
• Prebiotic inulin content supports gut microbiome

Burdock (Arctium lappa)

• Inulin content supports gut microbiome diversity and reduces intestinal permeability
• Arctigenin demonstrates hepatoprotective and anti-inflammatory effects in multiple studies
• Supports lymphatic drainage and elimination pathways
• Antioxidant chlorogenic acid reduces oxidative stress

Turmeric (Curcuma longa)

• Curcumin reduces liver inflammation via NF-κB and COX-2 inhibition
• Reduces ALT and AST in NAFLD clinical trials
• Improves insulin sensitivity and reduces fasting glucose
• Antifibrotic — inhibits TGF-β1 and hepatic stellate cell activation
• Bioavailability is critical — standard curcumin has <1% oral bioavailability; choose piperine-enhanced, liposomal, or phytosome (Meriva) formulations

Globe Artichoke (Cynara scolymus)

• Cynarin and luteolin stimulate bile production and liver cell regeneration
• Reduces total cholesterol and LDL via inhibition of HMG-CoA reductase
• Clinical trials show reduction in liver enzymes and liver fat
• Hepatoprotective against oxidative damage

Berberine

• Activates AMPK — a master metabolic regulator that reduces fat synthesis (inhibits SREBP-1c), improves insulin sensitivity, and promotes fat oxidation
• Multiple RCTs demonstrate reduction in liver fat, ALT, AST, triglycerides, and fasting glucose
• Comparable to metformin in several metabolic parameters
• Also modulates gut microbiome — increases Akkermansia muciniphila, a key metabolic health bacterium
• Clinical dose: 500mg 2–3x daily with meals. Note: may interact with certain medications — consult your practitioner.

Schisandra (Schisandra chinensis)

• Lignans (schisandrin B) protect liver cells from oxidative damage and lipid peroxidation
• Supports phase I and II liver detoxification enzyme activity
• Adaptogenic — reduces cortisol-driven metabolic stress via HPA axis modulation
• Improves mitochondrial function in liver cells

Liquorice Root (Glycyrrhiza glabra)

• Glycyrrhizin demonstrates anti-inflammatory and antifibrotic effects in NAFLD
• Reduces ALT and AST in clinical studies
• Inhibits 11β-HSD1 — reducing local cortisol activation in liver and adipose tissue
• Note: use deglycyrrhizinated (DGL) form for long-term use to avoid blood pressure and potassium effects. Avoid in hypertension.

Andrographis (Andrographis paniculata)

• Andrographolide activates AMPK and reduces hepatic lipid accumulation
• Anti-inflammatory via NF-κB inhibition
• Emerging evidence for NAFLD benefit; traditionally used for liver and immune support

---

Key Nutrients & Supplements: Complete Reference Table

Omega-3 Fatty Acids (EPA/DHA)

Reduce hepatic triglyceride synthesis and increase fat oxidation. Anti-inflammatory via resolution pathways (resolvins, protectins, maresins). Multiple meta-analyses confirm reduction in liver fat and enzymes. We recommend O.N.E. Omega or Pro-Resolve Omega for high-potency EPA/DHA support, or Algae Omega for a plant-based option.

Clinical dose: 2–4g EPA+DHA daily. Use triglyceride-form fish oil for superior absorption.

Vitamin E

Potent antioxidant; reduces oxidative stress-driven liver damage. The landmark PIVENS trial demonstrated 800 IU/day of vitamin E improved NASH histology (steatosis, inflammation, ballooning) in non-diabetic adults — one of the few interventions with histological evidence. Use mixed tocopherols including tocotrienols; avoid synthetic dl-alpha-tocopherol.

Magnesium

Improves insulin sensitivity; acts as a cofactor for over 300 enzymatic reactions including glucose metabolism and ATP production. Deficiency is extremely common in insulin-resistant states — up to 60% of type 2 diabetics are magnesium deficient. Epidemiological data consistently links higher magnesium intake with lower NAFLD risk and less severe fibrosis. We recommend RN Labs Magnesium Glycinate 180c or UltraMag Magnesium.

Forms: magnesium glycinate or malate for best absorption and tolerability.

N-Acetyl Cysteine (NAC)

Precursor to glutathione — the liver's primary and most abundant antioxidant. Glutathione is rapidly depleted in NAFLD/NASH due to chronic oxidative stress. NAC replenishes glutathione, reduces liver inflammation, and supports phase II detoxification (conjugation reactions). Available in our dispensary: Augmented NAC 90caps and CodeAge Liposomal NAC+ Platinum 120c.

Probiotics & Prebiotics

Gut dysbiosis is a key driver of NAFLD via the gut-liver axis. Altered microbiome composition increases intestinal permeability, allowing bacterial endotoxins (LPS) to enter portal circulation and activate hepatic inflammation. Lactobacillus and Bifidobacterium strains reduce liver fat, ALT, and endotoxin levels in clinical trials. Consider HealthZone Super Probiotics 90caps or BePure Two Probiotics 60 caps.

Zinc

Zinc deficiency is common in NAFLD and correlates with disease severity. Zinc is essential for antioxidant enzyme function (superoxide dismutase), liver cell integrity, and immune regulation. Supplementation reduces ALT, AST, and oxidative stress markers in clinical trials.

Vitamin D

Vitamin D receptors are expressed on hepatic stellate cells — vitamin D signalling inhibits their activation and reduces fibrosis. Low vitamin D is independently associated with more severe NAFLD and fibrosis. Test 25-OH vitamin D levels; aim for 100–150 nmol/L. Supplement with D3 + K2 for optimal effect.

---

Emerging Treatments & Research

GLP-1 Receptor Agonists (Semaglutide/Ozempic, Liraglutide)

GLP-1 agonists — originally developed for type 2 diabetes — have shown remarkable effects on NAFLD/NASH in clinical trials. The LEAN trial (liraglutide) and NASH trials (semaglutide) demonstrated significant reductions in liver fat, NASH resolution, and fibrosis improvement. Semaglutide is now being studied specifically for NASH in phase 3 trials. These medications work via weight loss, improved insulin sensitivity, and direct hepatic effects on lipid metabolism.

FXR Agonists

The farnesoid X receptor (FXR) regulates bile acid metabolism, lipid synthesis, and glucose homeostasis in the liver. FXR agonists (obeticholic acid, cilofexor) are in advanced clinical trials for NASH and have shown fibrosis reduction in phase 2/3 studies.

Thyroid Hormone Receptor-β Agonists

Resmetirom (Rezdiffra) — a selective thyroid hormone receptor-β agonist — was approved by the FDA in March 2024 for NASH with moderate-to-advanced fibrosis. It is the first drug approved specifically for NASH and works by activating thyroid hormone signalling in the liver, reducing fat synthesis and improving mitochondrial function.

Akkermansia muciniphila

This next-generation probiotic bacterium is emerging as a key player in metabolic health. Reduced Akkermansia abundance is consistently found in NAFLD, obesity, and insulin resistance. Supplementation with pasteurised Akkermansia improves insulin sensitivity, reduces liver fat, and decreases intestinal permeability in early clinical trials.

Functional Testing Worth Considering

For a comprehensive picture, consider discussing with your healthcare practitioner:

• Fasting insulin + HOMA-IR — assess insulin resistance directly
• Full lipid panel including triglycerides, HDL, LDL particle size
• HbA1c and fasting glucose — assess glycaemic control
• Liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin)
• GGT — sensitive marker of oxidative stress, liver stress, and alcohol intake
• FIB-4 score — calculate from standard blood tests; estimates fibrosis risk
• Uric acid — elevated in fructose excess and insulin resistance
• Ferritin — elevated in NASH; iron overload worsens liver damage; check transferrin saturation
• Homocysteine — marker of methylation capacity and B vitamin status
• 25-OH Vitamin D — assess vitamin D status
• TSH, free T3, free T4 — assess thyroid function; subclinical hypothyroidism worsens NAFLD
• hsCRP — high-sensitivity C-reactive protein; marker of systemic inflammation
• Comprehensive stool analysis — assess gut microbiome diversity, intestinal permeability markers (zonulin), and dysbiosis
• Organic acids test — assess mitochondrial function, oxidative stress, and nutritional deficiencies

---

When to See a Doctor

Seek medical assessment if you have:

• Persistently elevated liver enzymes (ALT, AST, GGT) on blood tests
• Ultrasound findings of fatty liver or increased liver echogenicity
• Unexplained fatigue, right upper abdominal discomfort, or jaundice
• Known risk factors: obesity, type 2 diabetes, metabolic syndrome, PCOS, hypothyroidism
• Family history of liver disease or cirrhosis
• Any symptoms of advanced liver disease (fluid retention, easy bruising, confusion)

NAFLD is a serious condition that warrants proper medical diagnosis and monitoring. Natural and lifestyle interventions are powerful — but they work best alongside, not instead of, appropriate medical care.

---

A Note on Medications

Resmetirom (Rezdiffra) became the first FDA-approved medication specifically for NASH with moderate-to-advanced fibrosis in March 2024. It is not yet available in New Zealand. Beyond this, management remains primarily lifestyle-based. Medications used to address underlying conditions (metformin for insulin resistance, statins for dyslipidaemia) may have secondary liver benefits but are not primary NAFLD treatments.

Always work with your healthcare provider before making changes to any medications.

---

Frequently Asked Questions

Can NAFLD be reversed? Yes — simple steatosis (fatty liver) and even early NASH (F1–F2 fibrosis) can be fully reversed with sustained lifestyle intervention. Studies show that 10%+ weight loss combined with dietary change and exercise can resolve NASH histologically in the majority of patients.

How long does it take to reverse fatty liver? Liver fat can begin to reduce within 2–4 weeks of dietary change (particularly reducing sugar and refined carbohydrates). Significant improvement in liver enzymes typically occurs within 3–6 months. Fibrosis reversal takes longer — 12–24+ months of sustained intervention.

Is fatty liver painful? Most people with NAFLD have no pain. Some experience a dull ache or heaviness in the upper right abdomen. Significant pain is uncommon and warrants medical assessment.

Can I drink alcohol if I have NAFLD? Ideally, no — or at absolute minimum. Even moderate alcohol intake accelerates NAFLD progression. Abstinence is recommended for anyone with NASH or fibrosis.

Does fatty liver cause weight gain? NAFLD and weight gain share common causes (insulin resistance, poor diet) but NAFLD itself doesn't directly cause weight gain. However, impaired liver function can worsen metabolic dysfunction, making weight management harder.

Is NAFLD hereditary? Genetic variants (particularly PNPLA3 I148M) significantly increase susceptibility. If a parent or sibling has NAFLD or cirrhosis, your risk is elevated. However, lifestyle factors remain the primary driver — genetics loads the gun, lifestyle pulls the trigger.

Can children get NAFLD? Yes — paediatric NAFLD is increasingly common, particularly in overweight children. Dietary intervention and exercise are the primary treatments. Any child with persistently elevated liver enzymes or fatty liver on ultrasound should be assessed by a paediatric gastroenterologist.

---

Putting It All Together: A Practical Protocol

The most effective approach to NAFLD is multi-modal — addressing diet, movement, sleep, stress, gut health, and targeted supplementation simultaneously.

Foundation (start here):

1. Eliminate all sugar-sweetened beverages and fruit juice immediately
2. Remove refined carbohydrates and ultra-processed foods
3. Adopt a Mediterranean or low-carbohydrate dietary pattern
4. Move daily — start with 30-minute walks, build from there
5. Prioritise 7–9 hours of quality sleep

Supplement foundation protocol:

• Omega-3 (EPA/DHA): 2–3g daily with meals
• Magnesium glycinate: 300–400mg before bed
• Vitamin D3 + K2: 2000–5000 IU daily (test levels first)
• Quality probiotic: daily with food

Advanced protocol (add after 4–6 weeks):

• Liposomal milk thistle: as directed
• NAC: 600mg twice daily
• Berberine: 500mg with meals (if insulin resistance is present)
• Curcumin (bioavailable form): 500–1000mg daily

Monitor progress:

• Repeat liver function tests at 3 and 6 months
• Reassess metabolic markers (fasting insulin, HOMA-IR, triglycerides) at 6 months
• Consider FibroScan at 12 months if baseline fibrosis was present

---

This article is for educational purposes only and does not constitute medical advice. If you have been diagnosed with NAFLD or suspect liver disease, please consult a qualified healthcare professional before commencing any treatment protocol.